UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July ~~October 31~~10, ~~2025~~2026

Elite Health Systems Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-26575	52-1842411
(State of other jurisdiction of	(Commission	(I.R.S. Employer
(State of other jurisdiction ofincorporation or organization)	(CommissionFile Number)	(I.R.S. EmployerIdentification No.)
incorporation or organization)	File Number)	Identification No.)
1131 W 6th StreetOntario, CA		91762
(Address of principal executive offices)		(Zip Code)

1131 W 6th Street
Ontario, CA	91762
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code:

(~~949~~909) ~~249~~ 657-~~1170~~2705

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Item 5.07. Submission of Matters to a Vote of Security Holders.~~1

OnItem ~~September 26, 2025, Elite Health Systems Inc~~8. ~~(the “Company”) held a Special Meeting of the Stockholders of the Company (the “Special Meeting”) to vote on certain matters~~01. AOther ~~total of 21,939,924 shares of the Company’s common stock were eligible to vote at the Special Meeting~~Events. ~~Votes totaling 14,688,791 were voted, accordingly a quorum was present. The matters voted on at the Special Meeting were as follows:~~

1.On ToJuly ~~elect~~10, as2026, ~~directors to~~ the ~~Company’s~~ Board of Directors ~~the~~of ~~five~~Elite ~~nominees~~Health ~~named~~Systems, inInc. (the ~~the~~ “Company’s”) ~~proxy~~authorized ~~statement~~Company management to ~~serve~~review, ~~for~~consider aand ~~one-year~~pursue ~~term~~strategic alternatives involving ~~expiring at~~ the ~~2026 Annual Meeting of Stockholders and until their successors are elected and qualified;~~Company.

Nominee	Votes For	Votes Against	Abstentions/ Withheld
Dr. Prasad Jeereddi	14,632,106	56,685	0
Alan Gold	14,633,106	55,685	0
William Leimkuhler	14,633,106	55,685	0
William St. Lawrence	14,633,106	55,685	0
Dr. Haranath Policherla	14,688,791	0	0

The Company’s mission is to provide access to healthcare and offer other healthcare related services through its wholly-owned subsidiaries, Elite Health Plan, Inc. and Physician Support Systems Inc. However, the Company is operating in a highly competitive business environment with complex regulatory and operational challenges. In order to do be successful, the Company must significantly increase its health care membership, which will take significant capital and time.

2.The Tostrategic ~~vote~~review onauthorized aby ~~proposal to amend~~ the Company’s ~~Certificate~~Board of ~~Incorporation~~Directors towill ~~increase~~include ~~the~~consideration ~~aggregate~~of ~~number~~potential equity or debt capital, selling certain assets, including one or more of ~~shares~~its operating businesses, or other strategic financings or transactions, such as a merger or disposition of ~~common~~all ~~stock~~of ~~which~~its ~~the~~assets. ~~Company~~No ~~shall~~timetable ~~have~~has ~~the~~been ~~authority~~established to ~~issue~~achieve ~~from~~any transaction 25and there can be no assurance that any strategic transaction,~~000~~ if implemented,~~000~~ ~~shares~~will result or result in an increase in stockholder value. The Company may terminate its review at any time and may ultimately determine not to ~~50,000,000;~~pursue a strategic transaction.

Votes For		Votes Against		Abstentions/ Withheld
14,487,901		200,890		0

The Company’s failure to consummate a strategic transaction, including a financing, merger, sale or disposition of all or substantially all of its assets, or other strategic alternative, could have a material adverse effect on the Company’s liquidity, financial condition and ability to continue operations. There can be no assurance that any such transaction will be completed on acceptable terms, or at all.

3.The ToCompany ~~vote~~intends onto acontinue ~~proposal~~operating toits ~~approve~~business in the ~~Company’s~~ordinary ~~2025~~course ~~Equity~~during ~~Incentive~~this ~~Plan~~process. ~~with~~While 4this review is underway,~~500,000~~ ~~maximum~~the ~~aggregate~~Company ~~number~~remains offocused ~~shares~~on ofexecuting ~~common~~its ~~stock~~operational ~~subject~~plan to ~~the~~provide ~~plan;~~quality Medicare Advantage services and to grow its membership.

Votes For		Votes Against		Abstentions/ Withheld
14,497,016		191,775		0

4. To vote on a proposal to approve the acquisition of Physician Support Systems, Inc. (“PSS”) by issuing 3,158,000 shares of the Company’s common stock pursuant to the terms of a share exchange agreement between the Company and the stockholders of PSS;

Votes For		Votes Against		Abstentions/ Withheld
14,031,106		157,685		500,000

5. To ratify the appointment of Mercurius & Associates LLP as our independent auditors for the fiscal year ending December 31, 2025;

Votes For		Votes Against		Abstentions/ Withheld
14,688,791		0		0

6. To approve of possible adjournment of the Special Meeting from time to time to solicit additional proxies in favor of any one or more of the matters identified above for consideration at the Special Meeting if determined by the chairperson of the Special Meeting to be necessary or appropriate;

Votes For		Votes Against		Abstentions/ Withheld
14,622,906		65,885		0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 5, 2025
Date: July 10, 2026
	Elite Health Systems Inc.
	By:	/s/ ~~Dr.~~ Prasad Jeereddi
	Name:	~~Dr.~~ Prasad Jeereddi
	Title:	Chairman and CEO

Filing Compare · Elite Health Systems Inc.